Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MAIA Biotechnology, Inc. ( (MAIA) ) has provided an update.
On September 29, 2025, MAIA Biotechnology, Inc. announced a Securities Purchase Agreement for a private placement with accredited investors and a company director, issuing 1,733,766 shares of common stock and warrants to purchase additional shares, raising approximately $2.25 million. The proceeds will fund the initial costs of Step 1 of Part C of the Phase II trial THIO -101 and working capital, with the closing expected on October 1, 2025. Additionally, the company amended certain common stock purchase warrants to reduce the exercise price, enhancing its financial strategy and aligning director interests with shareholders.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. Its lead program involves ateganosine (THIO), a potential first-in-class cancer telomere targeting agent aimed at treating non-small cell lung cancer (NSCLC) patients with telomerase-positive cancer cells.
Average Trading Volume: 443,971
Technical Sentiment Signal: Sell
Current Market Cap: $52.79M
Learn more about MAIA stock on TipRanks’ Stock Analysis page.